Compare
Anebulo Pharmaceuticals, Inc. vs Turn Therapeutics Inc. vs Imunon, Inc. vs PRF Technologies Ltd.
| Latest fiscal year | Anebulo Pharmaceuticals, Inc. ANEB | Turn Therapeutics Inc. TTRX | Imunon, Inc. IMNN | PRF Technologies Ltd. PRFX |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $17.0K |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | -311.8% (computed) |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$8.48M | -$3.19M | -$14.50M | -$5.02M |
| EPS (Diluted) | -$0.25 | -$0.12 | -$6.83 | -$7.47 |
| Operating cash flow | -$6.35M | -$2.56M | -$13.90M | -$3.96M |
| Free cash flow | n/a | n/a | -$14.18M | -$3.96M |
| Cash & equivalents | $11.63M | $4.03M | $8.78M | $3.12M |
| Total assets | $12.15M | $12.16M | $12.29M | $12.00M |
| Total liabilities | $487.7K | $7.48M | $5.23M | $2.71M |
| Shareholders' equity | $11.66M | $4.69M | $7.06M | $8.54M |
| Return on year-end equity | -72.8% | -68.2% | -205.3% | -58.8% |
| Shares outstanding | 41.08M | 29.45M | 3.42M | 830.6K |
Revenue, most recent five fiscal years
| Fiscal year | Anebulo Pharmaceuticals, Inc. | Turn Therapeutics Inc. | Imunon, Inc. | PRF Technologies Ltd. |
|---|---|---|---|---|
| Latest | n/a | n/a | $500.0K Ended 2022-12-31 | $17.0K Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $500.0K Ended 2021-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $500.0K Ended 2020-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $500.0K Ended 2019-12-31 | n/a |
| 4 years earlier | n/a | n/a | $500.0K Ended 2018-12-31 | n/a |